Advertisement
Advertisement
EVO
Evotec SE - ADR
1.89
USDSponsored
0.00
0.00%
Aug 25, 15:59 UTC -4
Closed
After-Market
1.89
0.00
0.00%
EVO Earnings Reports
Positive Surprise Ratio
EVO beat 15 of 39 last estimates.
38%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$130.29M
/-$0.34
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
-20.50%
/+183.33%
Evotec SE - ADR earnings per share and revenue
On Aug 13, 2026, EVO reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.38 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 145.44 million, with a --% difference.
Looking ahead to Q3 26, 2 analysts forecast an EPS of -0.34 USD, with revenue projected to reach 130.29 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Evotec SE - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Evotec SE - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Evotec SE - ADR's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Evotec SE - ADR expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Evotec SE - ADR's next earnings report?
Based on 2
analysts, Evotec SE - ADR is expected to report EPS of -$0.34 and revenue of $130.29M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement